April 13, 2022 12:46 PM EDT

FDA addresses biopharma's diversity problem with new draft guidance

Nicole DeFeudis

Editor

Back in 2020 — as drugmakers struggled to enroll diverse populations in Covid-19 trials — the FDA released new guidance urging pharma companies to devise a plan …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA addresses biopharma's diversity problem with new draft guidance

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer

House passes Biosecure Act, sending Chinese biotech ban to Senate

Adcomm says Intercept's rare liver disease drug should not get full approval

Post-Hoc: Big promises built Moderna. They might also be its undoing

FDA ad­dress­es bio­phar­ma's di­ver­si­ty prob­lem with new draft guid­ance

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

FDA addresses biopharma's diversity problem with new draft guidance